Medtronic Needs to Regrow a Spine

Medtronic‘s (NYSE: MDT) third-fiscal-quarter revenue chart would make a good preschool test for finding the outlier. (Hint: Look for the parentheses.)

Segment Sales (in Millions) Increase (Decrease) at Constant Currencies
Cardiac rhythm disease management $1,243 2%
Spinal $842 (1%)
Cardiovascular $722 21%
Neuromodulation $394 8%
Diabetes $311 8%
Surgical technologies $239 12%
Physio-control $100 8%

To read more please CLICK HERE

Source: Company press release.


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button